Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Breccia, Massimo ^a   Girmenia, Corrado ^a   Latagliata, Roberto ^a   Loglisci, Giuseppina ^a   Santopietro, Michelina ^a   Federico, Vincenzo ^a   Petrucci, Luigi ^a   Serrao, Alessandra ^a   Salaroli, Adriano ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876793162     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.021     Document Type: Article

References (16)

1. Hochhaus A. First-Line management of CML: a state of the art review. JNatl Compr Canc Netw Suppl 2008; 2: S1-S10
2. Deininger MW, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571(IRIS) 8-year followup: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114:1126
3. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332-1339 doi:10.1038/sj.leu.2403401 PMid:15190258
4. Sinai P, Berg RE, Haynie JM, Egorin MJ, Ilaria RL Jr, Forman J. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J Immunol 2007; 178: 2028-2037 PMid: 17277106
5. Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008; 111: 5342-5349 doi:10.1182/blood-2007-12-128397 PMid: 18326818 PMCid:2396727
6. Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Camara R, Arranza E, Reino FG, Salvanes FR, Fernandez-Ranada JM, Munoz C. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 88: 762-768 PMid: 12857554
7. Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica 2008; 93: 1252-1255 doi: 10.3324/haematol. 12642 PMid: 18519520
8. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 4806-4813 doi: 10.1200/JCO.2007.15.8154 PMid:18519952
9. Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 2009; 33: 670-672 doi: 10.1183/09031936.00025408 PMid: 19251803
10. Speletas M, Vyzantiadis TA, Kalala F, Plastiras D, Kokoviadou K, Antoniadis A, Korantzis I. Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. Med Mycol 2008; 46:259-263 doi:10.1080/13693780701558969 PMid: 17885950
11. Lin JT, Lee MY, Hsiao LT, Yang MH, Chao TC, Chen PM, Chiou TJ. Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. Ann Hematol 2004; 83: 444-446 doi: 10.1007/s00277-003-0813-z PMid: 14689232
12. Ferrand H, Tamburini J, Mouly S, Bouscary D, Bergmann JF. Listeria monocytogenes meningitis following imatinib mesylateinduced monocytopenia in a patient with chronic myeloid leukemia. Clin Infect Dis 2005; 41:1684-1685 doi: 10.1086/498031 PMid: 16267747
13. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9:976-980 PMid:12631595
14. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47: 155-157 doi: 10.1080/14639230500236818
15. Bekkenk MW, Vermeer MH, Meijer CJ, Jansen PM, Middeldorp JM, Stevens SJ, Willemze R. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 2003; 102: 4243 doi:10.1182/blood-2003-07-2436 PMid: 14623772
16. Anthony N, Shanks J, Terebelo H. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate. Leuk Res 2010; 34:1250-1251 doi:10.1016/j.leukres.2010.05.019 PMid:20646761